Table 1.
Demographic and clinical characteristics of patients with and without peripheral artery disease (PAD).
| Overall | Non-PAD | PAD | P | |
|---|---|---|---|---|
| (n = 214) | (n = 72) | (n = 142) | ||
| Mean (SD) ‡ | ||||
| Age, years | 68 (11) | 68 (12) | 69 (10) | 0.36 |
| Ankle brachial index | 0.78 (0.26) | 1.08 (0.09) | 0.62 (0.16) | 0.001 |
| Demographics/comorbidities: N (%) ¶ | ||||
| Sex, male | 144 (67) | 49 (68) | 95 (67) | 0.87 |
| Hypertension | 143 (67) | 42 (58) | 101 (72) | 0.05 |
| Dyslipidemia | 162 (76) | 42 (58) | 120 (85) | 0.001 |
| Diabetes | 62 (29) | 7 (10) | 55 (39) | 0.001 |
| Smoking (current and past) | 178 (83) | 55 (76) | 123 (87) | 0.06 |
| Coronary artery disease | 63 (30) | 14 (19) | 49 (35) | 0.018 |
| Congestive heart failure | 5 (2) | 1 (1) | 4 (3) | 0.46 |
| Medications: N (%) ¶ | ||||
| Statins | 164 (79) | 44 (62) | 120 (87) | 0.001 |
| ACE-I/ARB | 109 (52) | 28 (39) | 81 (59) | 0.007 |
| Beta blockers | 61 (29) | 19 (27) | 42 (31) | 0.56 |
| Diuretics | 16 (8) | 3 (4) | 13 (10) | 0.17 |
| ASA | 123 (58) | 35 (49) | 88 (62) | 0.06 |
| Antiplatelets (Other than ASA) | 41 (19) | 11 (15) | 30 (21) | 0.30 |
| Rivaroxaban (low dose 2.5 mg oral twice daily) | 4 (2) | 0 (0) | 4 (3) | 0.15 |
‡
Compared using independent t-test;
¶
Compared using chi-square test; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid. Bold values represent statistically significant values (p < 0.05).